U.S. FDA grants approval for Jivi antihemophilic factor (recombinant), PEGylated-aucl in pediatric patients 7 to under 12 years of age with hemophilia A (congenital factor VIII deficiency). Press ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability. ... FDA Approves Sanofi’s Hemophilia Drug.

Hympavzi was one of two Pfizer hemophilia treatments approved by the FDA in 2024. The company has already removed the other—hemophilia B gene therapy Beqvez—from the market, saying it was ...